Cover Page

Articles in Press

Past Issues

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Editorial Commentary 
Adjuvant immunotherapy in hepatocellular carcinoma: effective for Asian only, or for all patients?
Héloïse Bourien, Julien Edeline
AME Clinical Trials Review  
2024;
2:
62  
(25 August 2024) 
PDF Full Text (46) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Maintenance strategies in first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer—one size does not fit all
Per Pfeiffer, Gabor Liposits, Line Tarpgaard
AME Clinical Trials Review  
2024;
2:
61  
(25 August 2024) 
PDF Full Text (48) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Navigating the future of axillary surgery in HER2+ breast cancer: insights and opportunities for change
Joseph Dux, David Euhus
AME Clinical Trials Review  
2024;
2:
60  
(25 August 2024) 
PDF Full Text (53) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Concurrent radiotherapy with capecitabine and pyrotinib in patients with HER2-positive breast cancer and brain metastases
Renata Duchnowska
AME Clinical Trials Review  
2024;
2:
59  
(25 August 2024) 
PDF Full Text (50) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Chemo-immunotherapy on localized gastroesophageal/gastric adenocarcinoma—hope or delusion?
Marcelo Porfirio Sunagua Aruquipa, Renata D’Alpino Peixoto
AME Clinical Trials Review  
2024;
2:
58  
(25 August 2024) 
PDF Full Text (63) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?
Anuja Abhyankar, Grace K. Dy
AME Clinical Trials Review  
2024;
2:
57  
(25 August 2024) 
PDF Full Text (104) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Precision oncology in small-cell lung cancer: a tough nut to crack
Quincy S. C. Chu
AME Clinical Trials Review  
2024;
2:
56  
(25 August 2024) 
PDF Full Text (41) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Beyond PACIFIC: efficacy of the dual inhibition of TGF-β and PD-L1 for stage III non-small cell lung cancer concurrent chemoradiotherapy treatment
Takehiro Uemura
AME Clinical Trials Review  
2024;
2:
55  
(25 August 2024) 
PDF Full Text (48) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Exploring novel combinations in the treatment of relapsed ovarian cancer: the MEDIOLA trial results
Margherita Turinetto, Chiara Rognone, Giorgio Valabrega
AME Clinical Trials Review  
2024;
2:
54  
(25 August 2024) 
PDF Full Text (45) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Expanding the horizons of suspected acute coronary syndrome management: insights from the RAPID-CTCA trial
Luca Saba
AME Clinical Trials Review  
2024;
2:
53  
(25 August 2024) 
PDF Full Text (42) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Combination and precision: ingredients for success in advanced gastric cancer
Eric Mehlhaff, Nataliya V. Uboha
AME Clinical Trials Review  
2024;
2:
52  
(25 August 2024) 
PDF Full Text (48) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Can compartment-based complete mesocolic excision improve outcomes in patients with right colon cancer with metastatic D3 nodes?
Devesh S. Ballal, Avanish P. Saklani
AME Clinical Trials Review  
2024;
2:
51  
(25 August 2024) 
PDF Full Text (43) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Nanoparticle-based drug delivery in advanced pancreatic ductal adenocarcinoma: is it time to deliver yet?
Zachary Coyne, Ronan Andrew McLaughlin, Harry Harvey, Jennifer J. Knox
AME Clinical Trials Review  
2024;
2:
50  
(25 August 2024) 
PDF Full Text (42) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Personalized neoantigen vaccines for patients with advanced hepatocellular carcinoma
Carla Castro-Alejos, Pablo Sarobe
AME Clinical Trials Review  
2024;
2:
49  
(25 August 2024) 
PDF Full Text (50) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Polo-like kinase 1 inhibitors in refractory colorectal cancer: deciphering the myth of synthetic lethality
Mariam Rojas, Laura Gonzalez, Marta Cascante, Joan Maurel
AME Clinical Trials Review  
2024;
2:
48  
(25 August 2024) 
PDF Full Text (48) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Precision combination therapies: shaping the future management of advanced hepatocellular carcinoma?
Georgia Zeng, Mark Danta
AME Clinical Trials Review  
2024;
2:
47  
(25 August 2024) 
PDF Full Text (44) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Multisegmented fully covered esophageal stent: a step to the side
Shamus R. Carr
AME Clinical Trials Review  
2024;
2:
46  
(25 August 2024) 
PDF Full Text (136) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Prolonging anticoagulation after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (STEMI) patients: still looking for the RIGHT path
Angelo Oliva, Roxana Mehran
AME Clinical Trials Review  
2024;
2:
45  
(25 August 2024) 
PDF Full Text (46) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer
Ruben Raychaudhuri, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu
AME Clinical Trials Review  
2024;
2:
44  
(25 August 2024) 
PDF Full Text (46) Peer Review File COI Form Open Access Get Permission
Review Article 
Prediction of lymphatic invasion for patients with early gastric cancer: a review
Elfriede Bollschweiler, Patrick S. Plum
AME Clinical Trials Review  
2024;
2:
43  
(25 August 2024) 
PDF Full Text (90) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?
Toyoaki Hida
Published online: 20 October 2023
PDF Full Text (2574) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
The immune “tsunami” has arrived at the shores of early-stage non-small cell lung cancer
Antonio Rossi, Ettore Mari, Domenico Galetta
Published online: 06 September 2023
PDF Full Text (2378) Peer Review File COI Form Open Access Get Permission
Editorial 
Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review
Kaiping Zhang
Published online: 31 May 2023
PDF Full Text (617) COI Form Open Access Get Permission
Editorial Commentary 
The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer
Igor Gómez-Randulfe, Raffaele Califano
Published online: 24 November 2023
PDF Full Text (565) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
Jairo A. Zuluaga, Leonardo Rojas, Oscar Arrieta, Andrés F. Cardona
Published online: 09 April 2024
PDF Full Text (586) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri
Published online: 09 April 2024
PDF Full Text (437) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC
Takahiro Karasaki
Published online: 01 February 2024
PDF Full Text (354) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges
Mingjia Li, Dwight H. Owen, Gregory A. Otterson
Published online: 18 December 2023
PDF Full Text (309) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Improving the efficacy of immunotherapy in patients with advanced or metastatic urothelial carcinoma: a new role for tyrosine kinase inhibitors in the treatment paradigm?
Roubini Zakopoulou, Maria Kyrkasiadou, Aristotle Bamias
Published online: 18 June 2024
PDF Full Text (314) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Combining neoadjuvant and adjuvant immunotherapy breathes more life into the growing body of lung cancer treatment paradigms
Hailey A. Theeuwen, Anthony W. Kim
Published online: 19 January 2024
PDF Full Text (323) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer
Lauren Tagliaferro Epler, Joel W. Neal
Published online: 29 January 2024
PDF Full Text (305) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)
Yuji Uehara, Aaron C. Tan
Published online: 06 June 2024
PDF Full Text (327) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Segmentectomy for partially solid non-small cell lung cancer: what counts—the resection or the patient?
Marco Chiappetta, Carolina Sassorossi
Published online: 17 October 2023
PDF Full Text (316) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Editorial commentary: the importance of staging hasn’t changed, but the procedure of choice has
Emily June Zolfaghari, Justin D. Blasberg
Published online: 23 October 2023
PDF Full Text (329) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Towards better outcomes: segmentectomy for ground-glass opacity-dominant non-small cell lung cancer 3 cm or less—insights from JCOG1211
Terumoto Koike, Toshiki Hasebe, Masaya Nakamura, Yuki Shimizu, Tatsuya Goto, Masanori Tsuchida
Published online: 07 October 2023
PDF Full Text (338) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Targeting TIGIT in lung cancer: will it stick to the wall?
Jiaxin Niu, Saba Radhi
Published online: 21 June 2024
PDF Full Text (319) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?
Shuai Wang, Haiying Cheng
Published online: 02 February 2024
PDF Full Text (309) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Optimizing the role of immunotherapy in the management of resectable non-small cell lung cancer
Laercio DaSilva, Meredith J. McAdams, Arun Rajan
Published online: 03 February 2024
PDF Full Text (280) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Commentary: is segmentectomy curative in patients with early-stage ground glass opacity predominant non-small cell lung cancer?
Abdulrahman Y. Hammad, Hiran C. Fernando
Published online: 09 January 2024
PDF Full Text (236) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
What is the most optimal postoperative chest tube placement method after lung resection?
Katsuhiro Okuda, Keisuke Yokota, Tsutomu Tatematsu, Risa Oda, Ryuji Nakamura
Published online: 12 December 2023
PDF Full Text (266) Peer Review File COI Form Open Access Get Permission

Journal Highlight more

AME Clinical Trials Review (AME Clin Trials Rev; ACTR) is an international, open-access, peer-reviewed online journal, publishing commentaries on all phases of clinical trials, including but not limited to the design, conduct, analysis, regulation and ethics. It is dedicated to sharing insights of the key opinion leaders to stimulate thought and discussion in clinical trials and facilitate the translation of the findings of clinical trials from bench to bedside, and to clinical practice. More >>

Announcement more

AME entered an official partnership with Publons to enhance wide-ranging recognition for reviewers

AME Publishing Company entered an official partnership with Publons, a product of Clarivate Analytic Company (which owns Web of Science, EndNote, ScholarOne, among many others), as... More >>

Full implementation of transparent peer review at AME Clinical Trials Review (ACTR)

With a commitment to openness and accountability, and to increase the level of transparency throughout our peer review process, our editorial office has decided to fully implement ... More >>

Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review

I am excited to announce the launch of AME Clinical Trials Review (ACTR), an open-access, peer-reviewed journal publishing commentaries on clinical trials in all phases. More >>

Publishing Information

AME Clinical Trials Review is published by AME Publishing Company

AME Publishing Company